Kyntra Bio, Inc. (KYNB) Stock Price & Analysis
Kyntra Bio, Inc. (KYNB) fell 0.57% to USD 7.03 as of July 25, 2026 at 04:24 UTC, according to Nexqual real-time market data.
KYNB last closed at USD 7.07; the session ranged USD 7.03–7.2 on volume of 2,676 shares. Market capitalization is $28.46M, with a 52-week range of USD 6.32–12.6 (NMS). Source: Nexqual, July 25, 2026 at 04:24 UTC.
Key Statistics (as of July 25, 2026 at 04:24 UTC)
| Price | USD 7.03 |
|---|---|
| Change | ▼ 0.57% (down) |
| Previous Close | USD 7.07 |
| Open | USD 7.1 |
| Day Range | USD 7.03 – 7.2 |
| 52-Week Range | USD 6.32 – 12.6 |
| Volume | 2,676 shares |
| Market Cap | $28.46M |
| Exchange | NMS |
Technical Analysis (KYNB)
Nexqual's technical model rates KYNB "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 04:24 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.81 (neutral) |
| vs SMA50 | Below (USD 7.06) |
| MACD | 0.01 (positive) |
Analyst Ratings (KYNB)
Wall Street analysts rate KYNB "None" based on 2 analysts, with a mean price target of USD 39 (range USD 35–43), per Nexqual as of July 25, 2026 at 04:24 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 39 |
| High Target | USD 43 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (KYNB)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -3.18 |
| Revenue Estimate | $2.01M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -3.76 vs est -3.36 ▼ miss |
| 2025-12-31 | USD -3.51 vs est -3.89 ▲ beat |
| 2025-09-30 | USD 49.61 vs est -4.01 ▲ beat |
| 2025-06-30 | USD -1.88 vs est 1 ▼ miss |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
Financials & Fundamentals (KYNB)
| Total Revenue | $7.44M |
|---|---|
| Revenue Growth (YoY) | +36.50% |
| Gross Margin | -253.78% |
| Operating Margin | -369.07% |
| Profit Margin | +2199.42% |
| Current Ratio | 3.61 |
| Total Cash | $87.24M |
| Total Debt | $19.25M |
| Free Cash Flow | $27.28M |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
Financial Health Score (KYNB)
Nexqual rates Kyntra Bio, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:24 UTC.
| Growth | Critical — Revenue -97% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $87M cash vs $19M debt, net cash position |
| Cash Flow | Strong — FCF $27M, 424% margin |
| Efficiency | Mixed — No data |
Ownership (KYNB)
| Insider Ownership | +2.02% |
|---|---|
| Institutional Ownership | +25.57% |
| Shares Outstanding | 4.05M |
| Float | 3.56M |
| Short % of Float | +2.76% |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
Leadership (KYNB)
Kyntra Bio, Inc. is led by Thane Wettig (age 60), CEO & Director, per Nexqual as of July 25, 2026 at 04:24 UTC.
| CEO & Director | Thane Wettig (age 60) |
|---|---|
| Senior VP & CFO | David DeLucia (age 36) |
| Head of People and Culture & Executive Director | Michelle Simonetti |
| Director of IR & Communications - LifeSci Advisors | Gaia Vasiliver-Shamis |
Major Backers & Investors (KYNB)
Notable institutional backers of Kyntra Bio, Inc. include Armistice Capital, LLC, Acadian Asset Management. LLC, Two Sigma Investments, LP, according to Nexqual as of July 25, 2026 at 04:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 9.88% |
| Acadian Asset Management. LLC | 2.61% |
| Two Sigma Investments, LP | 1.22% |
| HighTower Advisors, LLC | 0.98% |
| Fidelity | 0.88% |
| UBS Group AG | 0.68% |
| Renaissance Technologies | 0.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.4% |
| BlackRock | 2.08% |
| Geode Capital | 1.14% |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
From Kyntra Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
- The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
- It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
- The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | USD 7.9 | ▼ 2.77% |
| MGNX | MacroGenics, Inc. | USD 3.7 | ▼ 13.95% |
| KPTI | Karyopharm Therapeutics Inc. | USD 7.41 | ▲ 3.2% |
| AKBA | Akebia Therapeutics, Inc. | USD 1.22 | ▼ 3.17% |
| ENTA | Enanta Pharmaceuticals, Inc. | USD 12.78 | ▼ 2.14% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:24 UTC. This page is informational and not investment advice.